Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Allergic Rhinitis in 26 Major Markets
Allergic rhinitis (AR) is a condition caused by hypersensitivity of the nasal mucosa to allergens. AR constitutes a significant social and economic burden due to its frequency and association with other allergy symptoms, which negatively affects patients’ quality of life, school performance and work productivity, as well as global health economics.
This report provides the current prevalent population for allergic rhinitis across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Portugal, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several features of allergic rhinitis patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of allergic rhinitis include:
• Asthma
• Conjunctivitis
• Chronic otitis media with effusion
• Eustachian tube dysfunction
• Sleep impairment
• Obstructive sleep apnoea
• Rhinosinusitis
• Pollen-food cross-reactivity
• Laryngeal irritation
• Globus sensation
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global allergic rhinitis market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of allergic rhinitis and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of allergic rhinitis patients.
• Identification of allergic rhinitis patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of allergic rhinitis patients.
CONTENTS
• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR ALLERGIC RHINITIS
• FEATURES OF ALLERGIC RHINITIS PATIENTS
• TREATMENT OF ALLERGIC RHINITIS PATIENTS
• COMORBIDITIES OF ALLERGIC RHINITIS PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX
LIST OF TABLES AND FIGURES
• Table 1. Prevalence of allergic rhinitis, total (000s)
• Table 2. Prevalence of allergic rhinitis, males (000s)
• Table 3. Prevalence of allergic rhinitis, females (000s)
• Table 4. Patients with allergic rhinitis by AR subtype, total (000s)
• Table 5. Patients with allergic rhinitis by ARIA subtype, total (000s)
• Table 6. Allergic rhinitis patients with blocked nose, total (000s)
• Table 7. Allergic rhinitis patients with runny nose, total (000s)
• Table 8. Allergic rhinitis patients with itchy nose, total (000s)
• Table 9. Allergic rhinitis patients with sneezing, total (000s)
• Table 10. Allergic rhinitis patients with itchy or runny eyes, total (000s)
• Table 11. Patients with allergic rhinitis diagnosed by a physician, total (000s)
• Table 12. Patients with allergic rhinitis taking medication for the disease, total (000s)
• Table 13. Allergic rhinitis patients with asthma, total (000s)
• Table 14. Allergic rhinitis patients with chronic sinusitis, total (000s)
• Table 15. Allergic rhinitis patients with nasal polyps, total (000s)
• Table 16. Abbreviations and acronyms used in the report
• Table 17. USA prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 18. USA prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 19. Canada prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 20. Canada prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 21. France prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 22. France prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 23. Germany prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 24. Germany prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 25. Italy prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 26. Italy prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 27. Spain prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 28. Spain prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 29. UK prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 30. UK prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 31. Poland prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 32. Poland prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 33. Netherlands prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 34. Netherlands prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 35. Belgium prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 36. Belgium prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 37. Norway prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 38. Norway prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 39. Sweden prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 40. Sweden prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 41. Finland prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 42. Finland prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 43. Denmark prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 44. Denmark prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 45. Austria prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 46. Austria prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 47. Portugal prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 48. Portugal prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 49. Russia prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 50. Russia prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 51. Turkey prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 52. Turkey prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 53. Japan prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 54. Japan prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 55. China prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 56. China prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 57. South Korea prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 58. South Korea prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 59. India prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 60. India prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 61. Australia prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 62. Australia prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 63. Brazil prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 64. Brazil prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 65. Mexico prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 66. Mexico prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
• Table 67. Argentina prevalence of allergic rhinitis by 5-yr age cohort, males (000s)
• Table 68. Argentina prevalence of allergic rhinitis by 5-yr age cohort, females (000s)
